SG11201903723RA - Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety - Google Patents

Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Info

Publication number
SG11201903723RA
SG11201903723RA SG11201903723RA SG11201903723RA SG11201903723RA SG 11201903723R A SG11201903723R A SG 11201903723RA SG 11201903723R A SG11201903723R A SG 11201903723RA SG 11201903723R A SG11201903723R A SG 11201903723RA SG 11201903723R A SG11201903723R A SG 11201903723RA
Authority
SG
Singapore
Prior art keywords
international
inhibitor
bcl
pharmaceutically acceptable
compound
Prior art date
Application number
SG11201903723RA
Inventor
Ali Fattaey
Garrett Rhyasen
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of SG11201903723RA publication Critical patent/SG11201903723RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 May 2018 (11.05.2018) WIPO I PCT omit IIl °nolo III m 0II 1111111 ow (10) International Publication Number WO 2018/085342 Al (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C07D 495/04 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US2017/059464 (22) International Filing Date: 01 November 2017 (01.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/416,329 02 November 2016 (02.11.2016) US (71) Applicant: CURIS, INC. [US/US]; 4 Maguire Road, Lex- ington, MA 02421 (US). (72) Inventors: FATTAEY, Ali; 130 Dean Rd., Brookline, MA 02445 (US). RHYASEN, Garrett, W.; 14 York Rd., Princeton Junction, NJ 08550 (US). (74) Agent: HARLAN, Edgar, W.; Elmore Patent Law Group, P.C., 484 Groton Road, Westford, MA 01886 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Published: — with international search report (Art. 21(3)) (54) Title: COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIE- TY W O 20 18/085 3 42 Al (57) : The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a BCL-2 inhibitor; wherein the compound of Formula I or pharmaceutical- ly acceptable salt thereof and a BCL-2 inhibitor are administered in amounts which in combination are therapeutically effective. The in- vention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt there- of, a BCL-2 inhibitor and a pharmaceutically acceptable carrier or excipient. RO-NH
SG11201903723RA 2016-11-02 2017-11-01 Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety SG11201903723RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416329P 2016-11-02 2016-11-02
PCT/US2017/059464 WO2018085342A1 (en) 2016-11-02 2017-11-01 Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (1)

Publication Number Publication Date
SG11201903723RA true SG11201903723RA (en) 2019-05-30

Family

ID=62076339

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903723RA SG11201903723RA (en) 2016-11-02 2017-11-01 Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Country Status (15)

Country Link
US (1) US20180133223A1 (en)
EP (1) EP3535272A4 (en)
JP (1) JP2020500175A (en)
KR (1) KR20190077040A (en)
CN (1) CN109923117A (en)
AU (2) AU2017355385A1 (en)
BR (1) BR112019008698A2 (en)
CA (1) CA3040727A1 (en)
EA (1) EA201991069A1 (en)
IL (1) IL266135A (en)
MA (1) MA46728A (en)
MX (1) MX2019004842A (en)
PH (1) PH12019500858A1 (en)
SG (1) SG11201903723RA (en)
WO (1) WO2018085342A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022434B9 (en) 2011-04-01 2016-02-29 Кьюрис, Инк. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MA53619A (en) * 2018-09-11 2021-12-15 Curis Inc POLYTHERAPY WITH A PHOSPHOINONOSITIDE 3-KINASE INHIBITOR HAVING A ZINC-BINDING METAL
CN112778212B (en) * 2021-01-28 2022-03-15 苏州莱克施德药业有限公司 Synthesis method of cropanisin intermediate 2-aminopyrimidine-5-methyl carboxylate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017728A2 (en) * 2005-08-05 2007-02-15 Orchid Research Laboratories Limited Novel heterocyclic compounds
ES2544082T3 (en) * 2006-12-07 2015-08-27 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
SG196815A1 (en) * 2009-01-08 2014-02-13 Curis Inc Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
EA022434B9 (en) * 2011-04-01 2016-02-29 Кьюрис, Инк. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
UY34632A (en) * 2012-02-24 2013-05-31 Novartis Ag OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
ES2594078T3 (en) * 2012-10-10 2016-12-15 F. Hoffmann-La Roche Ag Process for preparing thienopyridine compounds
US10111897B2 (en) * 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity
US20150320755A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
MX2019004842A (en) 2019-06-20
EP3535272A1 (en) 2019-09-11
MA46728A (en) 2019-09-11
CN109923117A (en) 2019-06-21
JP2020500175A (en) 2020-01-09
WO2018085342A1 (en) 2018-05-11
AU2017355385A1 (en) 2019-05-30
AU2020227036A1 (en) 2020-09-17
IL266135A (en) 2019-06-30
PH12019500858A1 (en) 2019-12-02
EP3535272A4 (en) 2020-06-17
EA201991069A1 (en) 2019-10-31
US20180133223A1 (en) 2018-05-17
CA3040727A1 (en) 2018-05-11
KR20190077040A (en) 2019-07-02
BR112019008698A2 (en) 2019-07-16

Similar Documents

Publication Publication Date Title
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201809554VA (en) Methods of treating skin cancer by administering a pd-1 inhibitor
SG11201804674UA (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
SG11201900501RA (en) Cannabis composition
SG11201407533SA (en) Antiviral compounds
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201900689RA (en) Compounds and compositions and uses thereof
SG11201903348UA (en) Therapeutic compounds and methods of use thereof
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201809560QA (en) Enhancer of zeste homolog 2 inhibitors
SG11201901673SA (en) Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers
SG11201809162XA (en) 6-aminopyridin-3-yl thiazoles as modulators of ror?t
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201907217RA (en) Pharmaceutical combinations for treating cancer